< 生产厂家 价格 >

氢化可的松

氢化可的松用途

Hydrocortisone是肾上腺皮质分泌的类固醇激素或糖皮质激素。
点击显示

氢化可的松名称

[ CAS 号 ]:
50-23-7

[ 中文名 ]:
氢化可的松

[ 英文名 ]:
Hydrocortisone

[中文别名 ]:

[英文别名 ]:

氢化可的松生物活性

[ 描述 ]:

Hydrocortisone是肾上腺皮质分泌的类固醇激素或糖皮质激素。

[ 相关类别 ]:

信号通路 >> G 蛋白偶联受体/G 蛋白 >> 糖皮质激素受体
天然产物 >> 类固醇
研究领域 >> 炎症/免疫

[ 靶点 ]

Human Endogenous Metabolite


[体外研究]

氢化可的松(50nM)显示hCMEC/D3细胞中GR转录物的剂量依赖性下调。氢化可的松补充血清减少的细胞分化培养基导致hCMEC/D3单层中TER的显着增加[1]。氢化可的松处理的树突细胞(DC)显示MHC II分子,共刺激分子CD86和DC特异性标志物CD83的表达降低,以及IL-12分泌强烈降低。氢化可的松处理的DC抑制IFN-γ的产生,但诱导IL-4的释放增加而IL-5没有变化[2]。氢化可的松可减少缺血后氧化应激,灌注压和渗出物的形成。氢化可的松抑制syndecan-1,硫酸乙酰肝素和透明质酸的缺血后脱落,以及从驻留肥大细胞释放组胺[3]。

[细胞实验]

将细胞接种在胶原蛋白IV涂覆的transwell小室顶部,用于六孔板(直径24mm,膜材料:聚对苯二甲酸乙二醇酯(PET),0.4μm孔,孔密度1.6×106cm 2),密度为2.5×104 cells cm2每口井。当它们在第5天达到汇合时,将不同的实验细胞组转移到含有减少量的FCS的分化培养基中,并如所示用TNFα或氢化可的松处理。

[参考文献]

[1]. F?rster C, et al. Differential effects of hydrocortisone and TNFalpha on tight junction proteins in an in vitro model of the human blood-brain barrier. J Physiol. 2008 Apr 1;586(7):1937-49.

[2]. Bellinghausen I, et al. Inhibition of human allergic T-cell responses by IL-10-treated dendritic cells: differences from hydrocortisone-treated dendritic cells. J Allergy Clin Immunol. 2001 Aug;108(2):242-9.

[3]. Chappell D, et al. Hydrocortisone preserves the vascular barrier by protecting the endothelial glycocalyx. Anesthesiology. 2007 Nov;107(5):776-84.


[相关活性小分子]

3-甲基腺嘌呤 | N-乙酰半胱氨酸 | 维生素A酸; 视黄酸 | 褪黑素 | 地诺前列酮 | 米非司酮 | 烟酰胺 | 5'-三磷酸腺苷 | 对乙酰氨基苯酚 | 列腺素 E1 | 去氢表雄酮 | 肾上腺酮 | 孕酮; 黄体素; 黄体酮 | 二十二碳六烯酸 | 辅酶I

氢化可的松物理化学性质

[ 密度 ]:
1.3±0.1 g/cm3

[ 沸点 ]:
566.5±50.0 °C at 760 mmHg

[ 熔点 ]:
211-214 °C(lit.)

[ 分子式 ]:
C21H30O5

[ 分子量 ]:
362.460

[ 闪点 ]:
310.4±26.6 °C

[ 精确质量 ]:
362.209320

[ PSA ]:
94.83000

[ LogP ]:
1.43

[ 外观性状 ]:
结晶白色粉末

[ 蒸汽压 ]:
0.0±3.5 mmHg at 25°C

[ 折射率 ]:
1.595

[ 储存条件 ]:
室温,避光,干燥

氢化可的松MSDS

氢化可的松毒性和生态

CHEMICAL IDENTIFICATION

RTECS NUMBER :
GM8925000
CHEMICAL NAME :
Cortisol
CAS REGISTRY NUMBER :
50-23-7
LAST UPDATED :
199801
DATA ITEMS CITED :
45
MOLECULAR FORMULA :
C21-H30-O5
MOLECULAR WEIGHT :
362.51
WISWESSER LINE NOTATION :
L E5 B666 OV MUTJ A1 CQ E1 FV1Q FQ

HEALTH HAZARD DATA

ACUTE TOXICITY DATA

TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Intraperitoneal
SPECIES OBSERVED :
Rodent - rat
DOSE/DURATION :
150 mg/kg
TOXIC EFFECTS :
Biochemical - Metabolism (Intermediary) - effect on inflammation or mediation of inflammation
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Subcutaneous
SPECIES OBSERVED :
Rodent - rat
DOSE/DURATION :
449 mg/kg
TOXIC EFFECTS :
Nutritional and Gross Metabolic - weight loss or decreased weight gain
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Subcutaneous
SPECIES OBSERVED :
Rodent - mouse
DOSE/DURATION :
>500 mg/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Subcutaneous
SPECIES OBSERVED :
Rodent - rat
DOSE/DURATION :
175 mg/kg/85D-I
TOXIC EFFECTS :
Endocrine - changes in adrenal weight Nutritional and Gross Metabolic - weight loss or decreased weight gain
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Rodent - mouse
DOSE/DURATION :
140 mg/kg/7D-I
TOXIC EFFECTS :
Endocrine - changes in thymus weight Nutritional and Gross Metabolic - weight loss or decreased weight gain Related to Chronic Data - death
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Subcutaneous
SPECIES OBSERVED :
Rodent - mouse
DOSE/DURATION :
62 mg/kg/11D-I
TOXIC EFFECTS :
Endocrine - other changes
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
DOSE :
210 mg/kg
SEX/DURATION :
female 14 day(s) pre-mating
TOXIC EFFECTS :
Reproductive - Maternal Effects - uterus, cervix, vagina
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Intraperitoneal
DOSE :
80 mg/kg
SEX/DURATION :
female 14-15 day(s) after conception
TOXIC EFFECTS :
Reproductive - Effects on Newborn - biochemical and metabolic
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Subcutaneous
DOSE :
50 mg/kg
SEX/DURATION :
female 18 day(s) after conception
TOXIC EFFECTS :
Reproductive - Effects on Newborn - biochemical and metabolic
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Subcutaneous
DOSE :
330 mg/kg
SEX/DURATION :
female 1-22 day(s) after conception
TOXIC EFFECTS :
Reproductive - Specific Developmental Abnormalities - endocrine system Reproductive - Effects on Newborn - growth statistics (e.g.%, reduced weight gain)
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Subcutaneous
DOSE :
220 mg/kg
SEX/DURATION :
female 9-19 day(s) after conception
TOXIC EFFECTS :
Reproductive - Effects on Embryo or Fetus - fetotoxicity (except death, e.g., stunted fetus) Reproductive - Specific Developmental Abnormalities - endocrine system Reproductive - Effects on Newborn - biochemical and metabolic
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Subcutaneous
DOSE :
200 mg/kg
SEX/DURATION :
female 14-15 day(s) after conception
TOXIC EFFECTS :
Reproductive - Effects on Embryo or Fetus - fetotoxicity (except death, e.g., stunted fetus)
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Intramuscular
DOSE :
500 mg/kg
SEX/DURATION :
female 13 day(s) after conception
TOXIC EFFECTS :
Reproductive - Effects on Embryo or Fetus - fetotoxicity (except death, e.g., stunted fetus) Reproductive - Specific Developmental Abnormalities - craniofacial (including nose and tongue)
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Parenteral
DOSE :
50 mg/kg
SEX/DURATION :
female 16-18 day(s) after conception
TOXIC EFFECTS :
Reproductive - Effects on Embryo or Fetus - other effects to embryo
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Parenteral
DOSE :
35 mg/kg
SEX/DURATION :
female 7 day(s) pre-mating
TOXIC EFFECTS :
Reproductive - Maternal Effects - uterus, cervix, vagina
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
DOSE :
10 mg/kg
SEX/DURATION :
female 11-14 day(s) after conception
TOXIC EFFECTS :
Reproductive - Specific Developmental Abnormalities - craniofacial (including nose and tongue)
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Intraperitoneal
DOSE :
400 mg/kg
SEX/DURATION :
female 11-14 day(s) after conception
TOXIC EFFECTS :
Reproductive - Fertility - post-implantation mortality (e.g. dead and/or resorbed implants per total number of implants) Reproductive - Specific Developmental Abnormalities - craniofacial (including nose and tongue)
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Subcutaneous
DOSE :
400 mg/kg
SEX/DURATION :
female 11-14 day(s) after conception
TOXIC EFFECTS :
Reproductive - Fertility - post-implantation mortality (e.g. dead and/or resorbed implants per total number of implants) Reproductive - Specific Developmental Abnormalities - craniofacial (including nose and tongue)
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Subcutaneous
DOSE :
156 mg/kg
SEX/DURATION :
female 11-14 day(s) after conception
TOXIC EFFECTS :
Reproductive - Specific Developmental Abnormalities - craniofacial (including nose and tongue)
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Subcutaneous
DOSE :
200 mg/kg
SEX/DURATION :
female 12 day(s) after conception
TOXIC EFFECTS :
Reproductive - Specific Developmental Abnormalities - craniofacial (including nose and tongue)
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Intramuscular
DOSE :
400 mg/kg
SEX/DURATION :
female 11-14 day(s) after conception
TOXIC EFFECTS :
Reproductive - Fertility - post-implantation mortality (e.g. dead and/or resorbed implants per total number of implants) Reproductive - Specific Developmental Abnormalities - craniofacial (including nose and tongue)
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Intramuscular
DOSE :
200 mg/kg
SEX/DURATION :
female 12 day(s) after conception
TOXIC EFFECTS :
Reproductive - Effects on Embryo or Fetus - fetotoxicity (except death, e.g., stunted fetus) Reproductive - Effects on Embryo or Fetus - fetal death
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Intraplacental
DOSE :
4 mg/kg
SEX/DURATION :
female 11 day(s) after conception
TOXIC EFFECTS :
Reproductive - Effects on Embryo or Fetus - fetal death Reproductive - Specific Developmental Abnormalities - other developmental abnormalities
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Subcutaneous
DOSE :
6 mg/kg
SEX/DURATION :
female 24-26 day(s) after conception
TOXIC EFFECTS :
Reproductive - Effects on Newborn - other neonatal measures or effects Reproductive - Effects on Newborn - growth statistics (e.g.%, reduced weight gain)
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Ocular
DOSE :
2945 ug/kg
SEX/DURATION :
female 6-18 day(s) after conception
TOXIC EFFECTS :
Reproductive - Effects on Embryo or Fetus - fetal death
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Subcutaneous
DOSE :
12 mg/kg
SEX/DURATION :
female 16-17 day(s) after conception
TOXIC EFFECTS :
Reproductive - Specific Developmental Abnormalities - eye/ear Reproductive - Specific Developmental Abnormalities - homeostasis
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Intramuscular
DOSE :
150 mg/kg
SEX/DURATION :
female 12 day(s) after conception
TOXIC EFFECTS :
Reproductive - Effects on Embryo or Fetus - fetotoxicity (except death, e.g., stunted fetus) Reproductive - Specific Developmental Abnormalities - craniofacial (including nose and tongue)
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Intramuscular
DOSE :
333 mg/kg
SEX/DURATION :
female 10 day(s) after conception
TOXIC EFFECTS :
Reproductive - Fertility - post-implantation mortality (e.g. dead and/or resorbed implants per total number of implants)
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Intramuscular
DOSE :
400 mg/kg
SEX/DURATION :
female 11 day(s) after conception
TOXIC EFFECTS :
Reproductive - Effects on Embryo or Fetus - cytological changes (including somatic cell genetic material) Reproductive - Specific Developmental Abnormalities - craniofacial (including nose and tongue)
TYPE OF TEST :
Unscheduled DNA synthesis
TYPE OF TEST :
DNA inhibition
TYPE OF TEST :
Cytogenetic analysis
TYPE OF TEST :
DNA inhibition

MUTATION DATA

TYPE OF TEST :
DNA inhibition
TEST SYSTEM :
Bird - chicken Embryo
DOSE/DURATION :
450 pmol/L
REFERENCE :
NATUAS Nature. (Nature Subscription Dept., POB 1018, Manasguan, NJ 08736) V.1- 1869- Volume(issue)/page/year: 257,804,1975 *** REVIEWS *** TOXICOLOGY REVIEW CLPTAT Clinical Pharmacology and Therapeutics (St. Louis). (C.V. Mosby Co., 11830 Westline Industrial Dr., St. Louis, MO 63146) V.1- 1960- Volume(issue)/page/year: 5,480,1964 TOXICOLOGY REVIEW ADVPA3 Advances in Pharmacology. (New York, NY) V.1-6, 1962-68. For publisher information, see AVPCAQ. Volume(issue)/page/year: 4,263,1966 *** NIOSH STANDARDS DEVELOPMENT AND SURVEILLANCE DATA *** NIOSH OCCUPATIONAL EXPOSURE SURVEY DATA : NOHS - National Occupational Hazard Survey (1974) NOHS Hazard Code - 80429 No. of Facilities: 1374 (estimated) No. of Industries: 12 No. of Occupations: 15 No. of Employees: 28935 (estimated) NOES - National Occupational Exposure Survey (1983) NOES Hazard Code - 80429 No. of Facilities: 1396 (estimated) No. of Industries: 7 No. of Occupations: 20 No. of Employees: 36900 (estimated) No. of Female Employees: 21576 (estimated)
点击显示

氢化可的松安全信息

[ 符号 ]:

GHS08

[ 信号词 ]:
Warning

[ 危害声明 ]:
H361

[ 警示性声明 ]:
P281

[ 个人防护装备 ]:
Eyeshields;full-face particle respirator type N100 (US);Gloves;respirator cartridge type N100 (US);type P1 (EN143) respirator filter;type P3 (EN 143) respirator cartridges

[ 危害码 (欧洲) ]:
Xn:Harmful

[ 风险声明 (欧洲) ]:
R62;R63

[ 安全声明 (欧洲) ]:
S36/37-S45

[ 危险品运输编码 ]:
2811.0

[ WGK德国 ]:
3

[ RTECS号 ]:
GM8925000

[ 危险类别 ]:
6.1

[ 海关编码 ]:
2937210000

氢化可的松合成路线

氢化可的松上下游产品

氢化可的松制备

可由肾上腺取液分离,也可用17α-羟基黄酮为原料经一系列反应制得。

点击显示

氢化可的松海关

[ 海关编码 ]: 2937210000

氢化可的松文献

Functional consequence of the MET-T1010I polymorphism in breast cancer.

Oncotarget 6(5) , 2604-14, (2015)

Major breast cancer predisposition genes, only account for approximately 30% of high-risk breast cancer families and only explain 15% of breast cancer familial relative risk. The HGF growth factor rec...

Cell-cell adhesions and cell contractility are upregulated upon desmosome disruption.

PLoS ONE 9(7) , e101824, (2014)

Desmosomes are perturbed in a number of disease states - including genetic disorders, autoimmune and bacterial diseases. Here, we report unexpected changes in other cell-cell adhesion structures upon ...

MYC is a critical target of FBXW7.

Oncotarget 6(5) , 3292-305, (2015)

MYC deregulation is a driver of many human cancers. Altering the balance of MYC protein levels at the level of transcription, protein stability, or turnover is sufficient to transform cells to a tumor...


更多文献

相关化工产品/化学物质:

相关药品:

推荐生产厂家/供应商:

公司名:南通润丰石油化工有限公司

区域:南通市崇川区

价格:
¥需询单/1kg ¥需询单/1ton

联系人:曹经理

产品详情:氢化可的松


公司名:上海吉至生化科技有限公司

区域:上海市奉贤区

价格:
¥68.0/20mg ¥178.0/5g ¥628.0/25g

联系人:刘佳

产品详情:氢化可的松


公司名:上海如吉生物科技发展有限公司

区域:上海市静安区

价格:
¥55.0/5g

联系人:蕾蕾

产品详情:氢化可的松


公司名:上海源溪生物科技有限公司

区域:上海市浦东新区

价格:
¥需询单/1g

联系人:赖经理

产品详情:Hydrocortisone (Cortisol)


公司名:上海脉铂医药科技有限公司

区域:上海市嘉定区

价格:
¥489.0/1g ¥539.0/1g ¥789.0/5g ¥需询单/1g

联系人:李先生

产品详情:Hydrocortisone


查看所有供应商请点击:

氢化可的松供应商


相关化合物

【氢化可的松】化源网提供氢化可的松CAS号50-23-7,氢化可的松MSDS及其说明、性质、英文名、生产厂家、作用/用途、分子量、密度、沸点、熔点、结构式等。CAS号查询氢化可的松上化源网,专业又轻松。>>电脑版:氢化可的松

标题:氢化可的松_MSDS_用途_密度_氢化可的松CAS号【50-23-7】_化源网 地址:https://m.chemsrc.com/mip/cas/50-23-7_749688.html